PCP
CRL icon

Perbak Capital Partners’s Charles River Laboratories CRL Stock Holding History

Perbak Capital Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,800
Closed -$728K – 314
2025
Q2 		$728K Buy
+4,800
New +$640K 0.16% 128

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Perbak Capital Partners's CRL Position: Q3 2025 in Review

Perbak Capital Partners sold out of Charles River Laboratories (CRL) in Q3 2025, closing a stake of 4,800 shares — an estimated $728K sold.

Perbak Capital Partners first reported a position in CRL in Q2 2025 and held it in 1 quarter. The position peaked at $728K in Q2 2025. 556 funds tracked by Wall St. Rank hold CRL as of Q3 2025.

  • Perbak Capital Partners reported no remaining Charles River Laboratories position as of Q3 2025 after selling out during the quarter.
  • Perbak Capital Partners sold 4,800 Charles River Laboratories shares in Q3 2025, an estimated $728K.
  • Perbak Capital Partners first reported a position in Charles River Laboratories in Q2 2025 and held it in 1 quarter.
  • Perbak Capital Partners's Charles River Laboratories position peaked at $728K in Q2 2025.
  • 556 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2025.

Based on Perbak Capital Partners's 13F filing for Q3 2025, filed 13 Nov 2025.